Acasti Pharma Ratios and Metrics

Market cap in millions USD. Fiscal year is April - March.

Millions USD. Fiscal year is Apr - Mar.

Year	Current	2022	2021	2020	2019	2018	2017	2016
Market Capitalization	27	21	54	108	34	80	25	15
Market Cap Growth	-	-62.03%	-49.83%	218.66%	-57.59%	214.55%	73.91%	-
Enterprise Value	9	-7	11	47	20	55	20	15
PE Ratio	-0.70	-0.48	-5.50	-5.47	-1.32	-2.02	-1.54	-1.70
PS Ratio	-	-	-	549.48	-	-	-	-
PB Ratio	0.58	0.30	0.50	1.94	2.60	7.22	4.04	-
P/FCF Ratio	-2.02	-1.29	-3.14	-7.49	-1.45	-3.15	-1.51	-1.39
P/OCF Ratio	-2.00	-1.29	-3.14	-7.52	-1.47	-3.22	-1.54	-1.70
EV/Sales Ratio	-	-	-	240.06	-	-	-	-
EV/EBITDA Ratio	-0.04	0.13	-1.02	-2.51	-0.89	-1.72	-1.56	-2.25
EV/EBIT Ratio	-0.04	0.13	-1.02	-2.39	-0.81	-1.61	-1.35	-1.70
EV/FCF Ratio	-0.15	0.43	-0.62	-3.27	-0.85	-2.18	-1.21	-1.39
Debt / Equity Ratio	0.00	0.01	0.00	0.00	0.01	0.12	0.20	-
Debt / EBITDA Ratio	0.00	-0.01	-0.03	0.00	-0.01	-0.04	-0.09	-
Debt / FCF Ratio	0.00	-0.03	-0.02	-0.01	-0.01	-0.05	-0.07	-
Quick Ratio	14.73	8.41	13.56	38.80	2.00	1.97	1.34	-
Current Ratio	15.19	8.59	13.89	39.50	2.50	2.05	1.42	-
Asset Turnover	0	0	0	0.01	0	0	0	-
Interest Coverage	-	-	-	-	-22.73	-6.94	-10.89	-67.53
Return on Equity (ROE)	-58.90%	-46.00%	-10.10%	-77.70%	-1049.40%	-545.60%	-150.30%	-
Return on Assets (ROA)	-50.60%	-38.40%	-9.30%	-62.10%	-92.10%	-133.20%	-92.80%	-
Return on Capital (ROIC)	-73.66%	-76.21%	-14.36%	-29.45%	-185.97%	-277.33%	-200.24%	-
Earnings Yield	-142.25%	-206.79%	-18.17%	-18.27%	-75.49%	-49.40%	-64.80%	-58.94%
FCF Yield	-36.08%	-77.64%	-31.90%	-13.36%	-68.85%	-31.77%	-66.17%	-72.18%
Buyback Yield / Dilution	-54.75%	-21.09%	-148.46%	-40.25%	-55.80%	-210.47%	-57.61%	-4.08%
Total Shareholder Return	-54.75%	-21.09%	-148.46%	-40.25%	-55.80%	-210.47%	-57.61%	-4.08%

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).